Aptose Biosciences Reports Promising Results in AML Therapy Trials

Aptose Biosciences ( (TSE:APS) ) just unveiled an announcement.

Aptose Biosciences announced promising results from its TUSCANY clinical trial, where the tuspetinib-based therapy showed excellent safety and complete responses in AML patients at increased dose levels. The company is now administering a 160 mg dose of tuspetinib, with previous doses achieving a 100% complete response rate, surpassing expectations. The data supports the use of tuspetinib with standard care across diverse AML populations, including those with adverse mutations, and has been accepted for presentation at the upcoming American Society of Hematology Annual Meeting.

The most recent analyst rating on (TSE:APS) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on Aptose Biosciences stock, see the TSE:APS Stock Forecast page.

Spark’s Take on TSE:APS Stock

According to Spark, TipRanks’ AI Analyst, TSE:APS is a Underperform.

Aptose Biosciences faces significant financial distress with no revenue generation and substantial losses. The negative technical indicators and valuation metrics further highlight the stock’s weak position. However, recent corporate events provide a glimmer of hope with potential advancements in AML treatment and strategic partnerships, slightly mitigating the overall risks. The stock remains risky, requiring cautious optimism for future developments.

To see Spark’s full report on TSE:APS stock, click here.

More about Aptose Biosciences

Aptose Biosciences Inc. is a clinical-stage precision oncology company focused on developing a tuspetinib-based triple drug frontline therapy for treating patients with newly diagnosed acute myeloid leukemia (AML).

Average Trading Volume: 2,997

Technical Sentiment Signal: Sell

Current Market Cap: C$5M

For detailed information about APS stock, go to TipRanks’ Stock Analysis page.